Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
05 janv. 2023 09h19 HE
|
Revive Therapeutics Ltd.
TORONTO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
22 déc. 2022 14h00 HE
|
Revive Therapeutics Ltd.
TORONTO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Ltd. Expands Life Offering to Quebec
15 déc. 2022 07h29 HE
|
Revive Therapeutics Ltd.
TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) announces that it is expanding its previously announced private placement...
Revive Therapeutics Ltd. Announces Offering of Up to $5 Million
30 nov. 2022 17h43 HE
|
Revive Therapeutics Ltd.
TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) is pleased to announce that it is arranging a private placement of a minimum...
Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
24 nov. 2022 09h18 HE
|
Revive Therapeutics Ltd.
TORONTO, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
22 nov. 2022 09h20 HE
|
Revive Therapeutics Ltd.
TORONTO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
14 oct. 2022 13h34 HE
|
Revive Therapeutics Ltd.
TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
06 oct. 2022 10h18 HE
|
Revive Therapeutics Ltd.
TORONTO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
28 sept. 2022 07h00 HE
|
Revive Therapeutics Ltd.
TORONTO, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program
16 sept. 2022 06h00 HE
|
Revive Therapeutics Ltd.
TORONTO, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...